// App-Quantinova.ai

: p53 Functional Assessment and Correlation with 17p Deletion and/or TP53 Mutation Status: Final Report of the ICLL001 Bomp Trial

Researchers

Presenter

  • Magali Le Garff-Tavernier

Principal Investigators

  • Lauren Veronese

  • Florence Nguyen-Khac

  • Pauline Robbe

  • Patricia Combes

  • Marie-Sarah Dilhuydy

  • Pierre Feugier

  • Beatrice Mahe

  • Laurence Sanhes

  • Alain Jacques Delmer

  • Loic Ysebaert

  • Malgorzata Truchan-Graczyk

  • Brigitte Dreyfus

  • Choquet Sylvain

  • Thrse Aurran

  • Emmanuelle Ferrant

  • Caroline Dartigeas

  • Stphane Leprtre

  • Gian Matteo Pica

  • Frederic Davi

  • Bruno Pereira

  • Roselyne Delepine

  • Anna Schuh

  • Romain Guieze

  • Jacques-Olivier Bay

  • Vronique Leblond

  • Helene Merle-Beral

  • Sophie de Guibert

  • Olivier Tournilhac

Medical Centers

  • Sorbonne Université Paris 6-INSERM UMRS 1138, Service d'Hématologie Biologique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

  • University Hospital of Clermont-Ferrand, Histocompatibility Laboratory, Clermont-Ferrand, France

  • Hôpital Pitié-Salpêtrière,Paris,France

  • Oxford Molecular Diagnostics Centre, University of Oxford, Radcliffe Department of Medicine, Oxford, United Kingdom

  • Service cytogénétique, CHU Estaing, Clermont-Ferrand, France, Clermont-Ferrand, France

  • CHU de Bordeaux, Pessac, France

  • Department of Haematology, Centre Hospitalier Régional Universitaire de Nancy, Vandoeuvre Les Nancy, France

  • Pediatric Hematology, Nantes University Hospital, Nantes, France

  • Service d'Hématologie, Centre Hospitalier de Perpignan, Perpignan, FRA

  • Hopital Robert Debre, CHU de Reims, Reims, France

  • CH Saumur, Saumur, France

  • Poitiers University Hospital / INSERM CIC 1402, Poitiers, France

  • LOC network, La Pitie Salpetriere Hospital, Assistance Publique Hopitaux de Paris, Paris, France

  • Institut Paoli-Calmettes, Marseille, France

  • Department of Hematology, Centre Hospitalier Lyon-Sud, University Claude Bernard Lyon 1, Pierre Benite, France

  • Service d'hématologie clinique et de thérapie cellulaire, CHU Bretonneau, Tours, France

  • Inserm U1245 and Department of Hematology, Centre Henri Becquerel and Normandie Univ UNIROUEN,Rouen,France

  • Service of Hematology, Centre Hospitalier Métropole Savoie, Chambery, France

  • Hôpita Pitié Salpétrière, Paris

  • Méthodologie - Biostatistique - Data-management, CHU de Clermont-Ferrand, Clermont-Ferrand, France

  • Toulouse University Hospital, Toulouse, France

  • Oxford University Hospitals NHS Trust, Oxford, United Kingdom

  • Clinical Hematology, University Hospital of Clermont-Ferrand, Unit of adult cell therapy and clinical hematology, Clermont Ferrand, France

  • Service d'Hematologie Clinique et de Therapie Cellulaire, CHU, Universite d'Auvergne, EA7453, CIC501, Clermont-Ferrand, FRA

  • Department of Clinical Hematology, AP-HP Hopital Pitie-Salpetriere, Paris, France

  • Surgical Pathology Department, Pitie Salpetriere Hospital, Paris, France

  • Centre Hospitalier Pontchaillou, Rennes, France

  • Service d'Hematologie Clinique et de Therapie Cellulaire, CHU, Universite d'Auvergne, EA7453, CIC501, Clermont-Ferrand, FRA

Locations

  • France

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • p53

  • Tumor protein p53

  • Ataxia-telangiectasia mutated

Drug/Treatment

  • Methylprednisolone

  • Bendamustine

  • ofatumumab Intravenous

  • Etoposide

  • Etoposide phosphate

  • TP53

  • Techniclone TNT

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01612988

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved